The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 31, 2019

Filed:

Oct. 13, 2014
Applicant:

Medtronic Minimed, Inc., Northridge, CA (US);

Inventors:

Sarnath Chattaraj, Simi Valley, CA (US);

Kiem H. Dang, Thousand Oaks, CA (US);

Hsi Chung Fusselman, Simi Valley, CA (US);

Poonam S. Gulati, La Canada, CA (US);

Lance P. Hoffman, West Hollywood, CA (US);

Guangping Zhang, Calabasas, CA (US);

Assignee:

MEDTRONIC MINIMED, INC., Northridge, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/727 (2006.01); A61M 5/142 (2006.01); A61K 38/28 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61M 5/158 (2006.01); A61M 5/168 (2006.01);
U.S. Cl.
CPC ...
A61K 31/727 (2013.01); A61K 38/28 (2013.01); A61L 29/08 (2013.01); A61L 29/16 (2013.01); A61M 5/14248 (2013.01); A61M 5/158 (2013.01); A61L 2300/236 (2013.01); A61L 2300/41 (2013.01); A61L 2300/42 (2013.01); A61M 5/16827 (2013.01); A61M 5/16836 (2013.01); A61M 2005/1586 (2013.01); A61M 2205/0205 (2013.01); A61M 2205/0238 (2013.01);
Abstract

Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.


Find Patent Forward Citations

Loading…